Samsara Sells 61,287 vTv Shares For Investors Who Redeemed Their Fund Interests
The shares sold carried no economic interest for the fund's general partner or the managing member overseeing it.
Samsara BioCapital sold 61,287 shares of vTv Therapeutics, which develops oral treatments for metabolic and inflammatory diseases, Thursday at $17.60 each. The fund's amended SEC ownership disclosure filed Monday said the block sale was for limited partners who had redeemed their fund interests.
Redeemed Investors Owned The Sale Proceeds
Neither Samsara BioCapital GP, the fund's general partner, nor Srinivas Akkaraju, its managing member, had an economic interest in the shares sold. Samsara held those shares solely for the benefit of the departing limited partners.
Akkaraju also manages Samsara Opportunity Fund GP, the general partner overseeing Samsara Opportunity Fund. His roles give him authority over voting and sales of the vTv securities held by both funds.
The ownership reporting relationship began on March 5, 2024. Amendments followed on September 3, September 25 and December 9, 2025.
Warrants Limit The Reported Stake
Akkaraju's reported beneficial ownership—the securities attributed to him through his control and applicable options—was 412,654 shares. The cover page listed 9.9%, rounded down because of filing-system field limits.
The percentages used 4,011,465 outstanding Class A shares as of November 5, 2026, plus applicable warrants and options exercisable within 60 days. Samsara BioCapital reported 247,069 shares, or 6.1%; Samsara Opportunity Fund reported 159,186, or 3.9%. Those interests overlap with the securities attributed to Akkaraju.
The funds directly held 187,443 and 106,000 common shares, respectively. They also held pre-funded and common warrants—rights to buy shares—whose terms prohibit exercises that would take ownership, including affiliates and other attribution parties, above 9.99%. That restriction currently limits the reporting persons to 412,654 shares of beneficial ownership. Akkaraju separately held 6,399 vested options or options scheduled to vest within 60 days.
A Diabetes Pill Alongside Insulin
vTv's lead candidate, cadisegliatin, is being tested in a late-stage trial as a pill used alongside insulin for type 1 diabetes. The trial plans to enroll 150 patients.
A mid-stage type 2 diabetes trial began in the Middle East with partner G42 Investments funding it. vTv also has diabetes and inflammation candidates licensed to partners, including HPP737, whose global rights belong to Newsoara BioPharma. vTv is eligible for milestone payments and sales royalties under that license.
The Thursday sale concerned shares held for redeemed investors; the remaining reported ownership includes fund securities subject to the warrant exercise ceiling.